[Form 4] Channel Therapeutics Corporation Insider Trading Activity

Rhea-AI Filing Summary

Pelthos Therapeutics Inc. (PTHS) – Form 4 insider filing dated 07/07/2025

The filing reports initial equity compensation granted to director Ezra M. Friedberg on 2 July 2025, shortly after the company executed a 1-for-10 reverse stock split on 1 July 2025.

• Restricted Stock Units (RSUs): 19,108 RSUs convertible into common shares. Vesting is quarterly over three years, with an effective exercise/conversion price stated as $13.50.
• Stock Options: 58,230 options with a $13.50 strike price, also vesting quarterly across three years and expiring 02 July 2035.
• Post-grant holdings: Friedberg now beneficially owns 28,012 derivative securities (RSUs) and 58,230 stock options; no change to his reported direct common-share ownership was disclosed.
• Role: Filing confirms Friedberg’s status as an independent director and that the submission is made solely by one reporting person.

The awards are typical non-derivative incentive grants aimed at aligning board oversight with shareholder interests. Because the instruments are unexercised derivatives subject to multi-year vesting, near-term share-count dilution is limited. No open-market transactions, sales, or purchases of outstanding common stock were reported.

Positive

• Aligned incentives: Multi-year RSU and option grants tie board compensation to share performance.

Negative

• Potential dilution: Up to 77,338 new shares could enter the float upon full vesting/exercise, modestly expanding the share count.

Insights

Financial Analyst

TL;DR – Routine director equity grant; neutral fundamental impact, minor potential dilution once vested.

The Form 4 details standard long-term incentive awards—19,108 RSUs plus 58,230 options—issued at a $13.50 reference price only one day after Pelthos’ 1-for-10 reverse split. Vesting spans three years, delaying any share issuance until FY-2026 at the earliest. With no accompanying common-share transaction, cash flow and current EPS remain unaffected. For investors, the filing signals continued efforts to retain and motivate board talent but does not materially shift the equity structure or investment thesis. Overall impact is neutral; monitor cumulative option overhang in future proxy statements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis Todd C

(Last) (First) (Middle)

C/O PELTHOS THERAPEUTICS INC.

4020 STIRRUP CREEK DRIVE, SUITE 110

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pelthos Therapeutics Inc. [ PTHS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$13.5	07/02/2025		A		19,108		07/02/2026(1)	07/02/2035	Common Stock	19,108	(1)	36,969(3)	D
Stock Option	$13.5	07/02/2025		A		58,230		07/02/2026(2)	07/02/2035	Common Stock	58,230	(2)	58,230	D

Explanation of Responses:

1. On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years.

2. On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years.

3. The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

	/s/ Todd C. Davis	07/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Pelthos Therapeutics (PTHS) report on July 7 2025?

Director Ezra M. Friedberg received 19,108 RSUs and 58,230 stock options granted on July 2 2025.

What is the exercise price of the newly granted PTHS options?

Both the RSUs (convertible) and the options reference an exercise price of $13.50 per share.

When do the RSUs and options granted to Ezra Friedberg vest?

They vest on a quarterly basis over three years, beginning after the July 2 2025 grant date.

Does the Form 4 indicate any open-market purchase or sale of PTHS common stock?

No. The filing only covers new equity awards; no direct purchases or sales of existing shares were reported.

How many derivative securities does Friedberg hold after the transaction?

He beneficially owns 28,012 RSUs and 58,230 stock options following the grant.